KLP Kapitalforvaltning AS Invests $532,000 in Denali Therapeutics Inc. (NASDAQ:DNLI)

KLP Kapitalforvaltning AS acquired a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 26,100 shares of the company's stock, valued at approximately $532,000.

A number of other large investors also recently bought and sold shares of DNLI. PNC Financial Services Group Inc. lifted its position in shares of Denali Therapeutics by 30.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock valued at $77,000 after buying an additional 885 shares during the last quarter. KBC Group NV lifted its position in Denali Therapeutics by 75.8% during the fourth quarter. KBC Group NV now owns 6,334 shares of the company's stock valued at $129,000 after acquiring an additional 2,731 shares during the last quarter. AlphaQuest LLC lifted its position in Denali Therapeutics by 177.1% during the fourth quarter. AlphaQuest LLC now owns 6,961 shares of the company's stock valued at $142,000 after acquiring an additional 4,449 shares during the last quarter. E Fund Management Co. Ltd. boosted its stake in Denali Therapeutics by 32.2% in the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock valued at $204,000 after acquiring an additional 2,436 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in Denali Therapeutics by 128.8% in the fourth quarter. SG Americas Securities LLC now owns 11,003 shares of the company's stock worth $224,000 after purchasing an additional 6,195 shares during the last quarter. Institutional investors own 92.92% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several brokerages have recently commented on DNLI. Deutsche Bank Aktiengesellschaft initiated coverage on Denali Therapeutics in a report on Tuesday, February 11th. They set a "buy" rating and a $31.00 price objective for the company. Robert W. Baird started coverage on Denali Therapeutics in a research note on Tuesday, January 7th. They issued an "outperform" rating and a $31.00 price target for the company. B. Riley restated a "buy" rating and set a $35.00 price target (down previously from $38.00) on shares of Denali Therapeutics in a research note on Wednesday, March 5th. Morgan Stanley began coverage on shares of Denali Therapeutics in a research report on Friday, March 7th. They issued an "overweight" rating and a $33.00 price objective for the company. Finally, William Blair reissued an "outperform" rating on shares of Denali Therapeutics in a research report on Friday, February 28th. Two research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $37.20.

Denali Therapeutics Stock Down 1.1 %

Shares of DNLI stock traded down $0.13 on Tuesday, hitting $11.47. The company had a trading volume of 2,582,205 shares, compared to its average volume of 1,069,415. Denali Therapeutics Inc. has a twelve month low of $10.57 and a twelve month high of $33.33. The firm has a market cap of $1.67 billion, a P/E ratio of -4.16 and a beta of 1.58. The company has a 50-day moving average price of $17.35 and a 200-day moving average price of $22.25.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.08. Equities research analysts expect that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.